A usual fresh cycle at the accredited partner hospitals in India would be ₹1,50,000 to ₹3,50,000 (AUD 2,775-6,475/GBP 1,430-3,330). This is inclusive of the cost of monitoring, egg retrieval, fertilization, and embryo culture, with only one embryo transfer. However, stimulation drugs will be extra (₹50,000-₹1,00,000). Add-on service such as.

India consistently offers the most affordable IVF for Australian and UK patients when the total cost (procedure + travel + accommodation) is considered. A full India IVF package — including a 12-day stay, flights from Australia, and the cycle — typically runs AUD 8,000–14,000 total. The procedure alone in Australia costs AUD 9,000–15,000. From the UK, a full India package — flights, accommodation, and cycle — typically runs £5,000–£9,000 total. This is comparable to the procedure-only cost at UK private clinics. Cyprus and the Czech Republic are affordable European alternatives but remain more expensive than India.

The main factors are: • Clinic operating costs — the largest driver of the India-Australia/UK price difference • Specialist and embryologist fees • Laboratory equipment and technology investment • Regulatory compliance costs • Which specific elements are part of or not included in the quoted price for the package treatment? In India, factors like clinic level, city, add-ons needed (ICSI, PGTA, donor eggs), and stimulation drugs used all influence the price.

The majority of patients get pregnant in the first to third rounds of IVF treatment. Live birth success rates of up to 51-68% have been achieved after three rounds of treatment for women below 38 years based on HFEA figures. Getting pregnant in the first round is doable, but not always possible. It largely hinges on a woman’s age during egg extraction, embryo quality, and uterus receptiveness. Two rounds of treatment should be budgeted for. India’s favorable price structure makes two rounds in India cheaper than one domestic round.

At NABH-accredited partner hospitals in India, live birth rates per embryo transfer are: • 40–50% for women under 35 • 30–40% for women aged 35–37 • 20–30% for women aged 38–40 • 10 – 18 % for women over 40 with their own eggs. The success rate for donor eggs is between 55 and 70 percent per transfer, irrespective of the age of the woman receiving the treatment. These percentages are supported by HFEA 2023 statistics as well as Monash IVF 2025 data from top fertility centers in the United Kingdom and Australia, respectively.

Common costs not always included in a base IVF package quote: • Stimulation medications: ₹50,000–₹1,00,000 • ICSI add-on: ₹20,000–₹50,000 • Embryo cryopreservation: ₹30,000–₹60,000 • PGT-A genetic testing: ₹50,000–₹1,50,000 per batch • Embryo storage: ₹20,000–₹40,000 per year; post-transfer medications. Divinheal provides a full itemised written cost estimate — including all potential add-ons — before any patient commits to travel. There are no placement fees.

Key criteria: • NABH or JCI accreditation — independent annual quality verification • Age-stratified live birth rates per transfer (not headline ‘success rates’) • Embryologist volume and experience • International patient department — English-speaking support, visa coordination, telemedicine follow-up • Single embryo transfer as the default policy. Divinheal applies all these criteria when selecting partner hospitals and can guide you to the right match for your specific diagnosis and budget.

Australia: There is no universally ‘free’ IVF in Australia. Medicare provides partial rebates on specific IVF procedure item numbers — typically reducing out-of-pocket costs by AUD 2,000–5,000 per cycle. There is no entitlement to a fixed number of funded cycles. Some state public fertility programmes offer subsidised IVF, but eligibility is strict, and wait-lists run 3–12 months. United Kingdom (UK): According to NICE guidelines, the NHS will fund up to three IVF cycles for eligible women who are below 40 years old. However, in reality, most CCGs pay for one to three cycles. The eligibility criteria differ widely between CCGs and can depend on factors such as age, body mass index (BMI), smoking, and whether either partner has had children before.

Eligible IVF patients in New South Wales can gain access to further financial assistance via the NSW Assisted Reproductive Technology (ART) subsidy scheme. This scheme involves offering rebates to patients other than what is offered under the Medicare scheme. The particular amount of rebate available as well as the eligibility criteria tend to vary regularly. Information in regard to this can be obtained from the NSW Department of Health or from Medicare Australia. The scheme is means-tested and requires certain criteria. Checking with the patient’s finance department of the fertility clinic is the surest way to establish the entitlements at the moment.

Wegovy (semaglutide — a GLP-1 receptor agonist) should be discontinued before starting an IVF cycle. Most fertility guidelines recommend stopping semaglutide at least 2 months before egg retrieval. GLP-1 medications have not been adequately studied in the context of ovarian stimulation and embryo implantation. Any weight loss achieved with Wegovy before discontinuation may support IVF outcomes. There is evidence linking a healthy BMI with improved ovarian reserve response. Discuss your medication history with your fertility specialist at the first consultation.

Botox is generally not recommended during an active IVF cycle — particularly during stimulation and the two weeks following embryo transfer. There is no large-scale clinical evidence linking Botox to reduced IVF success. However, the precautionary principle applies. Any elective cosmetic procedure during a fertility treatment cycle is best deferred. Most fertility specialists advise postponing Botox until after the pregnancy test result at day 10–14 post-transfer. If the test is positive, wait until after the first trimester.

Yes — HPV infection does not automatically disqualify a patient from IVF. There is no strong evidence that HPV positivity in the female partner directly reduces IVF success rates. Some research suggests HPV-infected sperm in male partners may reduce fertilisation rates, making ICSI a worthwhile consideration for these couples. Active abnormal cervical findings (e.g., CIN2+ requiring treatment) may need to be resolved before IVF. The treatment (LLETZ or similar) could affect the cervix used for embryo transfer. Your fertility specialist will assess your specific HPV status and cervical history at the pre-cycle consultation.

IVF is most successful when eggs are retrieved at younger ages. Live birth rates are highest in the mid-to-late 20s and begin declining measurably after 35. The decline is gradual between 30–35 and accelerates after 38. At 37, live birth rates at the top Indian centres are approximately 30–40%. By 42, they are typically 5–10% with their own eggs. However, donor egg IVF — using eggs from a younger donor — achieves 55–70% per transfer regardless of the recipient’s age. Acting sooner improves outcomes. There is no single age at which IVF becomes futile. Individual ovarian reserve (measured by AMH and antral follicle count) is a better predictor than age alone.

Standard health insurance policies in Australia and the UK generally do not cover IVF treatment performed abroad. Australian Medicare provides no rebate for treatment overseas. UK NHS coverage is UK-only. Some international or corporate health plans include overseas surgical benefits. Check your specific policy — fertility treatment coverage varies widely, even domestically. Divinheal provides itemised cost documentation from NABH-accredited hospitals for patients who wish to submit a claim or apply for employer health benefits.

The five stages are: • Ovarian stimulation — daily hormone injections for 8–14 days to produce multiple eggs • Egg retrieval — outpatient procedure under sedation, 20–30 minutes • Fertilisation — eggs and sperm combined in the lab (ICSI used for male factor infertility) • Embryo culture — embryos developed for 5–6 days to the blastocyst stage • Embryo transfer — one or two blastocysts are placed into the uterus via catheter. A pregnancy blood test follows 10–14 days later.